Manufacturers: REGENXBIO Inc.
RGX-314 (surabgene lomparvovec; ABBV-RGX-314) is an investigational AAV gene therapy developed by REGENXBIO in collaboration with AbbVie, in late-stage development as a one-time treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
RGX-314 (surabgene lomparvovec; ABBV-RGX-314) is an investigational AAV gene therapy developed by REGENXBIO in collaboration with AbbVie, in late-stage development as a one-time treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
For the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
2 associated conditions
